Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RTRX
  • CUSIP: N/A
  • Web: www.retrophin.com
Capitalization:
  • Market Cap: $644.74 million
  • Outstanding Shares: 38,173,000
Average Prices:
  • 50 Day Moving Avg: $18.21
  • 200 Day Moving Avg: $19.39
  • 52 Week Range: $15.88 - $24.57
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.81
  • P/E Growth: -0.79
Sales & Book Value:
  • Annual Revenue: $138.2 million
  • Price / Sales: 4.67
  • Book Value: $7.89 per share
  • Price / Book: 2.14
Profitability:
  • EBIDTA: ($23,610,000.00)
  • Net Margins: -32.96%
  • Return on Equity: -1.33%
  • Return on Assets: -0.79%
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 3.98%
  • Quick Ratio: 3.95%
Misc:
  • Average Volume: 375,803 shs.
  • Beta: 1.12
  • Short Ratio: 11.48
 

Frequently Asked Questions for Retrophin (NASDAQ:RTRX)

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its earnings results on Thursday, May, 4th. The company reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.23. The business had revenue of $33.62 million for the quarter, compared to the consensus estimate of $36.20 million. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The firm's revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 earnings per share. View Retrophin's Earnings History.

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?

4 brokerages have issued 1-year price objectives for Retrophin's stock. Their predictions range from $28.00 to $45.00. On average, they expect Retrophin's share price to reach $35.00 in the next year. View Analyst Ratings for Retrophin.

What are analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (5/3/2017)
  • 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Who are some of Retrophin's key competitors?

Who owns Retrophin stock?

Retrophin's stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (7.58%), Perceptive Advisors LLC (7.35%), FMR LLC (5.14%), Jennison Associates LLC (4.83%), Vanguard Group Inc. (3.96%) and State Street Corp (3.15%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur and Steve Aselage. View Institutional Ownership Trends for Retrophin.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Jennison Associates LLC, Morgan Stanley, Signpost Capital Advisors LP, American Century Companies Inc., Oxford Asset Management, Geode Capital Management LLC and Round Table Services LLC. Company insiders that have sold Retrophin stock in the last year include Alvin Shih and Steve Aselage. View Insider Buying and Selling for Retrophin.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., TIAA CREF Investment Management LLC, FMR LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Spark Investment Management LLC and Perceptive Advisors LLC. View Insider Buying and Selling for Retrophin.

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Retrophin stock cost?

One share of Retrophin stock can currently be purchased for approximately $16.89.

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (107.22% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/2/2017BMO Capital MarketsLower Price TargetOutperform$46.00 -> $45.00N/AView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Retrophin (NASDAQ:RTRX)
Earnings by Quarter for Retrophin (NASDAQ:RTRX)
Earnings History by Quarter for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Retrophin (NASDAQ:RTRX)
2017 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.19)($0.22)
Q2 20172($0.25)($0.19)($0.22)
Q3 20172($0.28)($0.18)($0.23)
Q4 20172($0.30)($0.17)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Retrophin (NASDAQ:RTRX)
Insider Ownership Percentage: 2.41%
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Retrophin (NASDAQ:RTRX)
Latest Headlines for Retrophin (NASDAQ:RTRX)
Source:
DateHeadline
finance.yahoo.com logoRetrophin to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 23 at 6:59 PM
americanbankingnews.com logoTheStreet Upgrades Retrophin Inc (RTRX) to "C-"
www.americanbankingnews.com - May 17 at 2:50 PM
finance.yahoo.com logoETFs with exposure to Retrophin, Inc. : May 12, 2017
finance.yahoo.com - May 12 at 10:59 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Expected to Announce Quarterly Sales of $36.71 Million
www.americanbankingnews.com - May 11 at 9:38 AM
finance.yahoo.com logoRetrophin, Inc. :RTRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 7:51 PM
americanbankingnews.com logoZacks: Analysts Expect Retrophin Inc (RTRX) to Post -$0.24 EPS
www.americanbankingnews.com - May 10 at 12:12 AM
finance.yahoo.com logoEdited Transcript of RTRX earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 7:58 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS
www.americanbankingnews.com - May 5 at 5:30 PM
seekingalpha.com logoRetrophin's (RTRX) CEO Steve Aselage on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 12:56 AM
globenewswire.com logoRetrophin Reports First Quarter 2017 Financial Results
globenewswire.com - May 4 at 7:54 PM
marketbeat.com logoRetrophin reports 1Q loss
marketbeat.com - May 4 at 6:57 PM
americanbankingnews.com logoRetrophin (RTRX) Given Coverage Optimism Rating of 0.03
www.americanbankingnews.com - May 3 at 3:05 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 9:34 AM
americanbankingnews.com logoRetrophin Inc (RTRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 3 at 12:30 AM
americanbankingnews.com logoFavorable Media Coverage Extremely Likely to Affect Retrophin (RTRX) Share Price
www.americanbankingnews.com - April 30 at 2:41 PM
americanbankingnews.com logoRetrophin Inc (RTRX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 7:36 AM
finance.yahoo.com logoRetrophin, Inc. – Value Analysis (NASDAQ:RTRX) : April 27, 2017
finance.yahoo.com - April 27 at 8:04 PM
americanbankingnews.com logoRetrophin (RTRX) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 27 at 5:45 PM
finance.yahoo.com logoRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : April 26, 2017
finance.yahoo.com - April 26 at 5:36 PM
finance.yahoo.com logoPharma bro Martin Shkreli asks judge to order document hand-over, bar other evidence
finance.yahoo.com - April 26 at 5:36 PM
americanbankingnews.com logoRetrophin (RTRX) Getting Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 6:34 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for Retrophin Inc's FY2019 Earnings (RTRX)
www.americanbankingnews.com - April 21 at 5:32 PM
americanbankingnews.com logoRetrophin (RTRX) Earns Media Sentiment Score of -0.03
www.americanbankingnews.com - April 20 at 8:35 PM
finance.yahoo.com logoRetrophin to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 20 at 7:43 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 19 at 7:54 AM
americanbankingnews.com logoRetrophin (RTRX) Given Media Impact Rating of 0.28
www.americanbankingnews.com - April 16 at 2:15 PM
americanbankingnews.com logoRetrophin (RTRX) Receives News Sentiment Rating of 0.01
www.americanbankingnews.com - April 13 at 3:50 PM
streetinsider.com logoRetrophin (RTRX) Names Ron Squarer to Board of Directors - StreetInsider.com
www.streetinsider.com - April 12 at 11:24 PM
globenewswire.com logoRetrophin Appoints Ron Squarer to Board of Directors - GlobeNewswire (press release)
globenewswire.com - April 12 at 6:22 PM
finance.yahoo.com logoEndo (ENDP) Reports Preliminary Results for First Quarter
finance.yahoo.com - April 11 at 7:26 PM
americanbankingnews.com logoRetrophin Inc Forecasted to Earn Q1 2017 Earnings of ($0.25) Per Share (RTRX)
www.americanbankingnews.com - April 10 at 7:10 AM
americanbankingnews.com logoRetrophin Inc (RTRX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 6 at 5:15 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Now Covered by William Blair
www.americanbankingnews.com - April 6 at 2:16 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Short Interest Down 0.3% in March
www.americanbankingnews.com - April 6 at 1:28 PM
zacks.com logoBioDelivery to Grant New Patents for its Marketed Drugs
www.zacks.com - April 3 at 8:46 AM
finance.yahoo.com logoWill Endo's Troubles Continue to Dent Performance in 2017?
finance.yahoo.com - March 28 at 7:28 PM
biz.yahoo.com logoRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 27 at 6:52 PM
streetinsider.com logoRetrophin (RTRX) Appoints John Orwin to Board of Directors
www.streetinsider.com - March 23 at 8:06 PM
finance.yahoo.com logoAlexion (ALXN) Licenses Artubus Technology for Rare Diseases
finance.yahoo.com - March 17 at 7:42 PM
finance.yahoo.com logoShire's (SHPG) Cinryze Label Expanded for Pediatric Use
finance.yahoo.com - March 16 at 8:30 PM
americanbankingnews.com logoRetrophin Inc (RTRX) Upgraded to Strong-Buy by Zacks Investment Research
www.americanbankingnews.com - March 13 at 2:48 PM
bizjournals.com logoMartin Shkreli’s former biotech company Retrophin is leaving Cambridge
www.bizjournals.com - March 9 at 7:37 PM
finance.yahoo.com logoRETROPHIN, INC. Financials
finance.yahoo.com - March 8 at 7:53 PM
biz.yahoo.com logoRETROPHIN, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
biz.yahoo.com - March 8 at 7:53 PM
finance.yahoo.com logoRetrophin to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 7 at 7:30 PM
finance.yahoo.com logoEdited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT
finance.yahoo.com - March 2 at 8:06 AM
us.rd.yahoo.com logoRetrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 1 at 7:54 PM
biz.yahoo.com logoQ4 2016 Retrophin Inc Earnings Release - After Market Close
biz.yahoo.com - March 1 at 10:11 AM
nasdaq.com logoNoteworthy Monday Option Activity: TSLA, RTRX, GME
www.nasdaq.com - February 27 at 4:26 PM
seekingalpha.com logoGreebel dubs Shkreli a 'serial liar' - Seeking Alpha
seekingalpha.com - February 23 at 8:13 AM

Social

Chart

Retrophin (RTRX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff